Antituberculosis drug-induced hepatotoxicity (ATDH) is a common adverse drug reaction often requiring treatment interruption, complicating tuberculosis management. The slow acetylator phenotype, characterized by reduced N-acetyltransferase 2 (NAT2) enzyme activity, is associated with increased hepatotoxicity risk, while rapid acetylators are associated with a higher risk of therapeutic failure. This study investigates the association between the NAT2 acetylation phenotype and ATDH occurrence, with an emphasis on its predictive value in regard to a multiethnic population and its impact on the timing of ATDH onset. A retrospective observational study was conducted on tuberculosis patients treated at Luigi Sacco Hospital, Milan, Italy (July 2020–September 2023). The NAT2 genotyping identified slow and rapid/intermediate acetylators. Cumulative incidence analysis and Fine–Gray competing risks regression models were used to assess ATDH risk and onset timing. Among 102 patients, 21.6% developed ATDH, including 16.7% with slow and 4.9% with rapid/intermediate acetylators. ATDH onset was significantly earlier in regard to slow acetylators (median 0.5 vs. 2 months, interquartile range-IQR: 0.5–3 vs. 1.7–5.5). Slow acetylators were associated with a higher risk of developing ATDH (Sub-distribution hazard ratio, SHR = 3.05; 95% confidence interval-CI: 1.17–7.95; p = 0.02), even after adjusting for confounders. The NAT2 acetylation phenotype strongly influences ATDH risk and timing. Early acetylator status identification may enable dose adjustments, enhancing treatment safety. These findings highlight the role of pharmacogenetics in optimizing antituberculosis therapy by improving efficacy and minimizing toxicity.
Acquired immune deficiency syndrome (AIDS) cholangiopathy has been a recognized clinical entity since the 1980s [ 1]. While the direct effects of human immunodeficiency virus (HIV) on hepatocytes and Kupffer cells are well described, the precise mechanisms leading to cholangiopathy remain incompletely understood. Current evidence suggests that, beyond HIV itself, coinfection with opportunistic pathogens plays a central role, as they trigger inflammatory responses that promote biliary strictures, obstruction, and cholestatic liver injury [ 2]. The condition is typically observed in individuals with advanced immunodeficiency (commonly defined as having a CD4 lymphocytes count of <0.2 × 109/L). Clinically, patients often present with cholestatic liver disease and biliary dilatation, though these findings are non-specific. As a result, AIDS-related cholangiopathy remains a diagnosis of exclusion [ 2, 3].